Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-...
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative treatments Proceeds will fund four clinical studies: two related to the …